drug_type
RELEVANT_DRUG
intervention_type
Biological: Cellular therapy (adoptive T-cell therapy)
drug_description
Donor PBMC-derived, partially HLA-matched cytotoxic T lymphocytes expanded to recognize AML1-ETO (RUNX1-RUNX1T1) fusion peptides; HLA-A*11:01 or HLA-A*02:01 restricted; TCR-mediated perforin/granzyme cytotoxicity against t(8;21) AML blasts.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Adoptive transfer of donor PBMC-derived cytotoxic T lymphocytes that have been selected and expanded for TCR specificity to AML1‑ETO (RUNX1‑RUNX1T1) fusion neoantigen peptides presented by HLA-A*11:01 or HLA-A*02:01. Upon antigen recognition on t(8;21) AML blasts, TCR engagement triggers perforin/granzyme-mediated cytolysis and cytokine-driven killing. Cells are not genetically engineered and require partial HLA matching for activity.
drug_name
Targeted AML1-ETO neoantigen cytotoxic T cells (CTL)
nct_id_drug_ref
NCT06499025